Compare AVAV & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAV | RPRX |
|---|---|---|
| Founded | 1971 | 1996 |
| Country | United States | United States |
| Employees | N/A | 99 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 16.4B |
| IPO Year | 2007 | 2020 |
| Metric | AVAV | RPRX |
|---|---|---|
| Price | $232.99 | $38.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $373.36 | $45.75 |
| AVG Volume (30 Days) | 1.1M | ★ 4.2M |
| Earning Date | 12-09-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 2.30% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.75 |
| Revenue | $1,369,870,000.00 | ★ $2,349,844,000.00 |
| Revenue This Year | $148.10 | $37.13 |
| Revenue Next Year | $17.19 | $1.48 |
| P/E Ratio | ★ N/A | $21.87 |
| Revenue Growth | ★ 79.89 | 3.70 |
| 52 Week Low | $102.25 | $24.05 |
| 52 Week High | $417.86 | $41.24 |
| Indicator | AVAV | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 30.05 | 47.08 |
| Support Level | $227.47 | $37.83 |
| Resistance Level | $240.29 | $38.90 |
| Average True Range (ATR) | 13.50 | 0.78 |
| MACD | -1.82 | -0.17 |
| Stochastic Oscillator | 8.28 | 21.35 |
AeroVironment Inc supplies unmanned aircraft systems, tactical missile systems, high-altitude pseudo-satellites, and other related services to government agencies within the United States Department of Defense as well as the United States allied international governments. The systems can help with security, surveillance, or sensing, and provide eyes in the sky without needing an actual person, or driver in the sky. The company is a defense technology provider delivering integrated capabilities across air, land, sea, space, and cyber. It develops and deploy autonomous systems, precision strike systems, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities. Company operates in three segments: UxS, LMS, MW.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.